RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9890
-0.0010 (-0.10%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.9900
Open0.9997
Bid0.989 x 3200
Ask1.050 x 1100
Day's Range0.9458 - 1.0448
52 Week Range0.8000 - 15.2400
Volume123,647
Avg. Volume232,416
Market Cap8.654M
Beta (3Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-6.283
Earnings DateMar 5, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.17
Trade prices are not sourced from all markets
  • Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
    PR Newswirelast month

    Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

    Standard of care temozolomide as a single agent increased median survival by 27% vs. control, therefore the combination of RGLS5579 plus temozolomide demonstrated synergistic efficacy in this model. RGLS5579 has completed the clinical candidate screening process demonstrating appropriate preliminary safety and drug-like properties.

  • Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
    PR Newswirelast month

    Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

    LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. As previously reported by the Company in July 2018, and in consultation with FDA, the Company voluntarily paused its ongoing Phase 1 Multiple Ascending Dose ("MAD") study of RGLS4326 in healthy volunteers due to unexpected observations in the 27-week mouse chronic toxicity study.  The Company terminated that mouse study prematurely at week 14.  The study was run in parallel to the Phase 1 program to enable initiation of the Phase 2 program in ADPKD patients upon completion of the Phase 1 MAD study.

  • Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
    Simply Wall St.2 months ago

    Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • GlobeNewswire3 months ago

    Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
    PR Newswire3 months ago

    Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme

    Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . ...

  • Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 24.36% and -10.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Regulus: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of $1.18 per share. The biopharmaceutical company posted revenue of $18,000 in the period. In the final minutes of trading on Thursday, the company's shares ...

  • Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
    PR Newswire3 months ago

    Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

    $47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Announces Successful Restructuring of Sanofi Collaboration
    PR Newswire3 months ago

    Regulus Announces Successful Restructuring of Sanofi Collaboration

    Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...

  • Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
    PR Newswire4 months ago

    Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • ACCESSWIRE4 months ago

    3 Healthcare Stocks To Watch On Tuesday

    Healthcare stocks have helped during times like these. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS). Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
    PR Newswire4 months ago

    Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Regains Compliance with NASDAQ Listing Requirements
    PR Newswire4 months ago

    Regulus Regains Compliance with NASDAQ Listing Requirements

    LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Therapeutics Announces Reverse Stock Split
    PR Newswire4 months ago

    Regulus Therapeutics Announces Reverse Stock Split

    The effective time of the reverse stock split was 5:00 p.m. ET on October 3, 2018.  The Company's shares will begin trading on a split-adjusted basis commencing upon market open on October 4, 2018. "Over the past several months, we have taken steps to reposition Regulus for long term sustainability.

  • Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
    PR Newswire5 months ago

    Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference
    PR Newswire5 months ago

    Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus Provides Pipeline Updates
    PR Newswire5 months ago

    Regulus Provides Pipeline Updates

    Hepatitis B virus (HBV) Programs: The Company has identified several microRNA targets that serve as host factors for the virus.  The Company's lead compound directed to one of the host microRNAs has demonstrated sub-nanomolar potency against HBV DNA replication and 95% reduction in HBsAg in in vitro studies.  The Company believes that targeting a host factor in the liver represents a unique mechanism of action for treatment of the virus compared to other programs in development and holds the potential for achieving a functional cure. The Company currently expects to file an IND for the HBV program in the second half of 2019, with the potential of achieving human proof-of-concept in a Phase 1 study. Glioblastoma multiforme (GBM) Program: The Company's lead anti-miR candidate targeting microRNA-10b demonstrated statistically significant improvements in survival as both a monotherapy as well as in combination with temozolamide (TMZ) in an orthotopic GBM animal model.

  • Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?
    Simply Wall St.5 months ago

    Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?

    The big shareholder groups in Regulus Therapeutics Inc (NASDAQ:RGLS) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning aRead More...

  • ACCESSWIRE6 months ago

    These Biotech Stocks Are Moving Higher in August

    GT Biopharma (GTBP) for example, recently announced that the company has a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota, has brought some attention to the company. Under the terms of the agreement, this Company will supply a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

  • Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks6 months ago

    Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 18.75% and -10.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Regulus: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 13 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • Regulus Reports Second Quarter 2018 Financial Results and Recent Updates
    PR Newswire6 months ago

    Regulus Reports Second Quarter 2018 Financial Results and Recent Updates

    Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway Amendment to Term Loan to Provide Additional Interest-Only Period LA JOLLA, Calif. , Aug. 9, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Stock Plunges on Cash Concerns Despite Restructuring
    Zacks7 months ago

    Regulus Stock Plunges on Cash Concerns Despite Restructuring

    Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.